CVS Health CorpCVSTOP PICKJul 26, 2022Stock price when the opinion was issued
As of Jun 05, 2026. Market Open.
Bought at less than 10x earnings with recent dividend increase is good for share price appreciation. Recent M&A also good for investors. Will continue to own shares. Excellent management team and solid dividend. Weakness is sector creating opportunities to buyout competitors.
Price target was raised today. This peaked in 2020-1 then was hit with a lot of bad news, like doubts over Signify and Oak Street acquisitions. But that negative sentiment has reversed, like their Medicare Advantage stars rating has gone up, and the street sees profitability rising in their pharmacy benefits management system, based on a new model last month. Trades under a cheap PE and pays a 3% dividend. He targets over $100 in 12 months. Is underloved and over-owned.
Healthcare has lagged this year. They run a chain of pharmacies, Aetna health insurance, pharmacy management and recently bought Oak Health. The CEO is doing a great job, and shares are not expensive around 8.5x PE. They took one some debt to bought some companies, but once they integrated them, it will ramp up cash flow.
(Analysts’ price target is $87.45)
CVS is a major pharmacy benefits manager providing tons of data to large companies like GM. He likes the pharmacy business, because it's much cheaper to go to the pharmacy for a vaccine instead of a hospital. Pharmacy will gain market share. CVS will return to dividend increases after their Aetna acquisition. Trades at 10x earnings. Very well-positioned. This is recession-proof. (Analysts’ price target is $116.70)